Steven Robinette

Steven Robinette is a Venture Partner at Atlas Venture and the Chief Executive Officer of Spolia Therapeutics, based in Boston, Massachusetts. Before assuming his current executive roles, he served as a Principal on the investment team at Atlas Venture and worked as an Engagement Manager at McKinsey & Company, where he focused on pharmaceutical research and development consulting. Robinette has been a founding team member for at least five publicly traded or acquired biotechnology companies, including Kymera Therapeutics, Disc Medicine, and Disarm Therapeutics, which was later acquired by Eli Lilly. He began his early scientific career as a Research Fellow at the National Institutes of Health and holds a doctorate in clinical medicine from Imperial College London. His professional focus centers on translating emerging biological research into innovative life sciences ventures and early stage therapeutics companies.